regulatory
confidence high
sentiment positive
materiality 0.90
FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price
VERTEX PHARMACEUTICALS INC / MA
- On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Wholesale acquisition cost (WAC) set at $2.2 million.
- CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy.